Diabetes mellitus and smoking among tuberculosis patients in a tertiary care centre in Karnataka, India by Jali, M V et al.
Public Health Action
Diabetes mellitus and smoking among tuberculosis patients 
in a tertiary care centre in Karnataka, India
M. V. Jali,1 V. K. Mahishale,2 M. B. Hiremath,1 S. Satyanarayana,3 A. M. V. Kumar,3 S. B. Nagaraja,4 
P. Isaakidis5
InternaƟ onal Union Against Tuberculosis and Lung Disease
Health soluƟ ons for the poor
VOL 3 SUPPLEMENT 1 PUBLISHED 4 NOVEMBER 2013
http://dx.doi.org/10.5588/pha.13.0031
Diabetes mellitus (DM) and smoking are risk factors for 
adverse outcomes in the treatment of tuberculosis (TB). 
In a tertiary care hospital at Belgaum in the South Indian 
State of Karnataka, all TB patients aged ⩾18 years con-
secutively diagnosed from February to September 2012 
were evaluated for DM and smoking. Of 307 TB patients, 
35.5% were found to have DM, 9.8% were current smok-
ers, and 3.6% had DM and were also smokers. Measures 
to assess and address both these factors need to be taken 
into account during TB treatment.
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consecutively during the period February to Septem-
ber 2012 who were referred to the DOTS centre for TB 
treatment were included in the study. All eligible pa-
tients were asked about their history of DM. If there 
was no known history of DM, patients underwent ran-
dom blood glucose (RBG) tests using a glucometer. Pa-
tients with RBG levels ⩾ 110 mg/dl (>6.1 mM) were 
requested to undergo a fasting blood glucose (FBG) 
test. Patients with FBG levels ⩾ 126 mg/dl (⩾7 mM) 
and between 110 and 125 mg/dl (6.1–7.0 mM) were 
diagnosed with DM and IFG, respectively, and referred 
for diabetes care. Simultaneously, TB patients with a 
history of at least one episode of tobacco smoking in 
the last 3 months were identiﬁ ed as ‘current smokers’. 
The procedure for screening, recording (in a separate 
register) and reporting (on a standard quarterly report-
ing form) has been described in detail elsewhere.6
Data variables, data entry and analysis
The following data were extracted from the registers: 
age, sex, type of TB, RBG levels, FBG levels, and history 
of at least one episode of smoking in the last 3 months. 
The data were entered into a pre-structured data entry 
form created in EpiData Version 3.1 (EpiData Associa-
tion, Odense, Denmark) and analysed. The data were 
summarised by frequencies and proportions.
Ethics approval
This project protocol was reviewed and approved by 
the International Union Against Tuberculosis and Lung 
Disease Ethics Advisory Group.
RESULTS
Of 307 patients referred to the DOTS centre, 247 
(80.5%) underwent all appropriate blood glucose tests 
and screening for current smoking status. About two 
thirds (64.2%) were male. Overall, 7.8% of patients had 
IFG, 35.5% had DM, 9.8% were current smokers and 
3.6% both had DM and were current smokers (Table). 
The prevalence of DM and smoking was higher among 
the younger age groups.
DISCUSSION
Despite India’s good Revised National TB Control Pro-
gramme, DM and tobacco consumption have the po-
tential to hamper TB control efforts. Research studies 
published recently in South India have found a high 
prevalence of DM among TB patients of approximately 
25% in the State of Tamil Nadu and 44% in the State 
of Kerala.6–8 These studies have shown that in addition 
Diabetes mellitus (DM) and tobacco smoking are independent risk factors for adverse tuberculosis 
(TB) treatment outcomes such as relapse, treatment 
failure and death.1,2 Individuals with DM who smoke 
⩾1 pack of cigarettes daily are at particularly high risk 
of death from TB.3 It has been recommended that TB 
patients should be routinely screened for both of these 
risk factors and that, if present, they should be ad-
dressed to improve TB treatment outcomes.3 
India, with an annual incidence of 2.2 million TB 
cases, has the highest TB burden in the world.4 Nearly 
63 million people (∼8% of the adult population aged 
⩾20 years) are estimated to have DM, and 120 million 
are estimated to be tobacco smokers (∼14% of the adult 
population).5 Previous studies have estimated the prev-
alence of diabetes and smoking among TB patients in-
dependently of each other, but none of these studies 
has screened for both conditions in the same setting 
and reported on the co-existence of both of these risk 
factors among TB patients.5 These data will be useful 
to assess the extent of DM care and smoking cessation 
services required during the course of TB treatment. In 
this study we report the prevalence of impaired fasting 
glucose (IFG), DM and current smoking in a cohort of 
TB patients diagnosed at a medical college teaching 
hospital in the South Indian state of Karnataka.
METHODS
Study setting
KLES Dr Prabhakar Kore Hospital is a 2400-bed hospital 
in the Belgaum district of Karnataka State in South India. 
TB patients diagnosed in the hospital are sent from var-
ious departments to the DOTS centre for TB treatment. 
Study design, study population, screening 
procedures, recording and reporting
This was a cross-sectional study involving record 
review. All TB patients aged ⩾18 years diagnosed 
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to DM, tobacco smoking needs to be addressed during 
TB treatment.9 Of note, all of the current smokers in the 
study were male, highlighting the cultural tradition in 
this part of the country for women not to smoke.
Independent international guidelines exist for the 
management of co-morbid conditions, such as DM, 
tobacco smoking, human immunodeﬁ ciency virus 
infection, etc., among tuberculosis patients.10–12 De-
pending on the local situation, national TB pro-
grammes in high TB burden countries need to adopt 
and incorporate these guidelines and integrate the im-
plementation and monitoring of the management of 
co-morbidities. This must begin at least in the tertiary 
care centres, where the resources and expertise are 
available and, based on the experiences gained, imple-
mentation can then be extended to the peripheral 
health facilities.
The strength of this study is that we implemented 
and documented the screening of both factors within 
the routine hospital system, with no special budget 
allocated to support these activities. With nearly 80% 
of the TB patients successfully undergoing screening 
for both conditions, it appears that screening is feasible. 
About 20% were not screened, and the exact reasons 
were not clear. As our facility is a tertiary care centre 
with many specialised services, we were able to link 
patients with these co-morbidities to appropriate care. 
The limitations of the study were that 1) it was im-
plemented in a tertiary care centre and the ﬁ ndings 
may not be generalisable, and 2) we deﬁ ned a current 
smoker as anyone who had smoked at least one tobacco 
product within the last 3 months, and documented 
this status. In India, tobacco products are either 
chewed or smoked—both of which are equally danger-
ous to personal health—and the consumption pattern 
of these two forms of tobacco varies widely across the 
country. As we mentioned the integration of services, 
we feel with hindsight that we should also have docu-
mented information on chewable forms of tobacco 
and used standardised deﬁ nitions. 
CONCLUSIONS AND 
RECOMMENDATIONS
It is feasible to screen for DM and tobacco smoking 
among TB patients in tertiary care settings. We recom-
mend that TB and DM clinics and smoking cessation 
services develop links towards an integrated, compre-
hensive package of services that could lead to im-
proved care and better patient outcomes.
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TABLE Prevalence of IFG, DM and smoking among a cohort of 
TB patients in Belgaum, India, January–September 2012
Characteristic
Total 
n
IFG
 n (%)*
DM only
n (%)*
Smoking 
only
 n (%)*
DM + 
smoking
 n (%)*
Total 307 24 (7.8) 109 (35.5) 30 (9.8) 11 (3.6)
Age, years
18–24  35  0   5 (14.3)  6 (17.1)  3 (8.6)
25–34  84  4 (4.8)  13 (15.5) 12 (14.3)  2 (2.4)
35–44  81  9 (11.1)  36 (44.4)  9 (11.1)  1 (1.2)
45–54  42 10 (23.8)  33 (78.6)  1 (2.4)  3 (7.1)
55–64  43  0  13 (30.2)  1 (2.3)  2 (4.7)
⩾65  22  1 (4.6)   9 (40.9)  1 (4.6)  0
Sex
Male 197 17 (8.6)  73 (37.1) 30 (15.2) 11 (5.6)
Female 110  7 (6.4)  36 (32.7)  0  0
Type of TB
New smear-positive 160  8 (5.0)  57 (35.6) 14 (8.8)  5 (3.1)
New smear-negative  49  3 (6.1)  29 (59.2)  2 (4.1)  1 (2.0)
New extra-pulmonary  36  3 (8.3)   9 (25.0)  3 (8.3)  1 (4.2)
Retreatment cases  55  4 (7.3)  13 (23.6) 10 (18.2)  4 (7.3)
Multidrug-resistant TB 
(resistant to isoniazid 
and rifampicin)   7  6 (85.7)   1 (14.3)  1 (14.3)  0
* Row percentages with denominator in Total column. 
IFG = impaired fasting glucose; DM = diabetes mellitus; TB = tuberculosis.
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Le diabète sucré (DM) et le tabagisme sont des facteurs de risque de 
mauvais résultats dans le traitement de la tuberculose (TB). Dans un 
hôpital de soins tertiaires à Belgaum dans l’Etat de Karnataka en Inde 
du Sud, tous les patients TB âgés de ⩾18 ans et diagnostiqués con-
sécutivement entre février et septembre 2012 ont été évalués en 
matière de DM et de tabagisme. Sur 307 patients TB, on a trouvé un 
DM chez 35,5%, un tabagisme actuel chez 9,8% et chez 3,6%, à la 
fois un DM et un tabagisme actuel. Il est indispensable d’incorporer 
des mesures d’évaluation et de réaction à ces deux facteurs au cours 
du traitement de la TB.
La diabetes sacarina (DM) y el tabaquismo representan factores de 
riesgo de alcanzar desenlaces terapéuticos desfavorables en el trata-
miento de la tuberculosis (TB). En un hospital de atención terciaria de 
Belgaum, en el estado de Karnataka del sur de la India, se investigaron 
el tabaquismo y la DM en todos los pacientes consecutivos de 
⩾18 años de edad, en quienes se estableció el diagnóstico de TB 
entre febrero y septiembre del 2012. De los 307 pacientes TB, se di-
agnosticó DM en el 35,5%, el 9,8% eran fumadores actuales y el 
3,6% eran diabéticos y fumadores actuales. Es necesario incorporar 
medidas de evaluación y de respuesta a estos dos factores durante el 
tratamiento de la TB.
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